



Celletricon files patent infringement suit against Fluxion Biosciences

Gothenburg, Sweden, 1 February 2010: Celletricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Celletricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Celletricon for microfluidic technology used in Celletricon's state-of-the-art ion channel drug screening solution, the Dynaflo[®]HT System. Celletricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Celletricon.

Annelie Skafte Persson, Celletricon's Chief Executive Officer, said "Celletricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Celletricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use."

Celletricon's Chairman **Lars-Eric Utterman** added "Celletricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today's litigation is a strategic step to defend Celletricon's intellectual property from being infringed."

About Celletricon

Celletricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Celletricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. Celletricon has developed two pioneering high throughput screening platforms in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess[®]HT System enables high throughput transfection for genomic screening and the Dynaflo[®]HT System greatly advances ion channel drug discovery.

Contact Details:

Annelie Skafte Persson, CEO

E-mail: annelie.skafte.persson@cellectricon.com

Susanne Fagerlund, VP Marketing & Communications

E-mail: susanne.fagerlund@cellectricon.com